Corrigendum to “Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches” [Lung Cancer 106 (2017) 70–75](S016950021730034X)(10.1016/j.lungcan.2017.02.002)

The authors regret the below error section ‘2.3. Atezolizumab, avelumab and durvalumab’ of the above referenced paper. The sentence ‘The ongoing phase III MYSTIC trial (NCT02453282) compares durvalumab with or without ipilimumab versus first-line platinum-based chemotherapy.’ Should read ‘The ongoing phase III MYSTIC trial (NCT02453282) compares durvalumab with or without tremelimumab versus first-line platinum-based chemotherapy.’ The authors would like to apologise for any inconvenience caused.